FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TORONTO, Sept. 15, 2017 -- Polydex Pharmaceuticals Limited (OTC MKTS:POLXF) (the “Company”) today announced financial results for the second quarter of the 2018 fiscal year. The three-month and six-month periods ending July 31, 2017 (together with comparative figures from the same periods in the previous fiscal year) are reported in U.S. dollars.
| 3 months ended July 31, 2017 | 3 months ended July 31, 2016 | 6 months ended July 31, 2017 | 6 months ended July 31, 2016 | ||||||
| Sales | $ | 1,274,622 | $ | 1,737,376 | $ | 2,534,707 | $ | 3,195,351 | |
| Net Income (loss) | (20,095 | ) | 280,936 | 129,064 | 356,744 | ||||
| Income | |||||||||
| per Common Share | |||||||||
| Basic | (0.01 | ) | 0.08 | 0.04 | 0.11 | ||||
| Diluted | (0.01 | ) | 0.08 | 0.04 | 0.10 | ||||
| Weighted average | |||||||||
| # Common Shares | |||||||||
| Basic | 3,399,978 | 3,380,478 | 3,399,978 | 3,380,478 | |||||
| Diluted | 3,399,978 | 3,517,388 | 3,507,275 | 3,535,363 | |||||
Sales in Canada were up 61% year to date to $487,711, despite a decrease in foreign sales. However, due to fluctuations in the exchange rates of the Canadian dollar, net income was impacted by a foreign exchange loss in the second quarter of $155,729 compared to a gain of $64,753 in the same period last year, resulting in a negative swing of $220,480.
EBITDA amounts to $47,244 for the quarter and $296,214 for the year to date.
“We have been working on the development of a new form of dextran and its product registration for potential use in several different applications,” said George Usher, President and CEO of the Company. “We continue to upgrade our systems on a priority basis where needed, with the prospect of increasing sales”.
ValuEngine upgraded shares of Polydex Pharmaceuticals Ltd. (OTCMKTS:POLXF) from a sell rating to a hold rating in a research report released last month. https://weekherald.com/2017/08/23/polydex-pharmaceuticals-ltd-polxf-upgraded-by-valuengine-to-hold.html
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote).
The Company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Information about the Company’s products is available at www.dextran.ca
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.
Contact:
Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621, ([email protected])
